This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...

Merck & Co. is leveraging March 4’s International HPV Awareness Day for a marketing campaign in China, lighting up landmark buildings in four megacities in the hopes of reigniting demand amid ...

The moves in China by the likes of Merck also come as the industry stares down a wave of generic drugs this year that has made the issue of securing new candidates all the more pressing.

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. Advertisement Article continues below this ad “We believe China still represents a ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...